We are live on ! Find out more
AA

AlphaCentric Advisors Portfolio holdings

AUM $100M
This Fund
S&P 500
This Quarter Est. Return
-2.91%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$136M
AUM Growth
-$30M
Cap. Flow
-$21.6M
Cap. Flow %
-15.92%
Top 10 Hldgs %
25.49%
Holding
262
New
34
Increased
55
Reduced
87
Closed
45

Top Buys

Rank Stock Value
1
ENOV icon
Enovis
ENOV
+$1.04M
2
AMPH icon
Amphastar Pharmaceuticals
AMPH
+$1.04M
3
QQQ icon
Invesco QQQ Trust
QQQ
+$958K
4
QQQM icon
Invesco NASDAQ 100 ETF
QQQM
+$955K
5
SRPT icon
Sarepta Therapeutics
SRPT
+$929K

Top Sells

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$2.16M
2
CORT icon
Corcept Therapeutics
CORT
+$2.14M
3
NARI
Inari Medical, Inc. Common Stock
NARI
+$2.13M
4
KALV
KalVista Pharmaceuticals
KALV
+$1.49M
5
CATX icon
Perspective Therapeutics
CATX
+$1.35M

Sector Composition

Rank Sector Weight
1 Healthcare 60.25%
2 Real Estate 12.98%
3 Financials 6.42%
4 Industrials 2.59%
5 Technology 2.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISRG icon
51
Intuitive Surgical
ISRG
$122B
$890K 0.66%
2,000
-1,000
-33% -$398K
VKTX icon
52
Viking Therapeutics
VKTX
$4.31B
$875K 0.64%
16,500
-1,500
-8% -$98.3K
PTGX icon
53
Protagonist Therapeutics
PTGX
$9.06B
$866K 0.64%
25,000
– –
SNY icon
54
Sanofi
SNY
$107B
$849K 0.63%
17,500
+2,500
+17% +$121K
CATX icon
55
Perspective Therapeutics
CATX
$341M
$818K 0.6%
82,000
-93,676
-53% -$1.35M
VRNA
56
DELISTED
Verona Pharma
VRNA
$810K 0.6%
56,000
– –
AGNC icon
57
AGNC Investment
AGNC
$12.9B
$808K 0.59%
84,646
– –
NVDA icon
58
NVIDIA
NVDA
$4.91T
$742K 0.55%
6,009
+5,329
+784% +$539K
NARI
59
DELISTED
Inari Medical, Inc. Common Stock
NARI
$722K 0.53%
15,000
-48,000
-76% -$2.13M
EMBC icon
60
Embecta
EMBC
$193M
$706K 0.52%
56,500
-55,000
-49% -$668K
DYN icon
61
Dyne Therapeutics
DYN
$3.92B
$706K 0.52%
20,000
– –
SYM icon
62
Symbotic
SYM
$5.25B
$703K 0.52%
20,000
-5,000
-20% -$202K
VALN
63
Valneva
VALN
$511M
$649K 0.48%
88,252
+26,248
+42% +$210K
ARAY icon
64
Accuray
ARAY
$30.8M
$637K 0.47%
350,000
– –
SGMT icon
65
Sagimet Biosciences
SGMT
$483M
$633K 0.47%
185,000
– –
RVNC
66
DELISTED
Revance Therapeutics, Inc.
RVNC
$630K 0.46%
245,000
– –
ONIT
67
Onity Group
ONIT
$344M
$613K 0.45%
25,567
– –
VYNE icon
68
VYNE Therapeutics
VYNE
$25.4M
$612K 0.45%
310,500
-134,500
-30% -$335K
PRCT icon
69
Procept Biorobotics
PRCT
$1.09B
$611K 0.45%
10,000
-15,000
-60% -$892K
SOUN icon
70
SoundHound AI
SOUN
$2.73B
$593K 0.44%
150,000
-50,000
-25% -$232K
AVAV icon
71
AeroVironment
AVAV
$7.2B
$574K 0.42%
3,150
-4,850
-61% -$872K
SHY icon
72
iShares 1-3 Year Treasury Bond ETF
SHY
$25.7B
$573K 0.42%
7,016
+1,558
+29% +$127K
CABA icon
73
Cabaletta Bio
CABA
$461M
$524K 0.39%
70,000
+5,000
+8% +$61.3K
BBJP icon
74
JPMorgan BetaBuilders Japan ETF
BBJP
$17.1B
$487K 0.36%
8,623
-124
-1% -$6.97K
EWA icon
75
iShares MSCI Australia ETF
EWA
$1.43B
$485K 0.36%
19,853
-841
-4% -$20.5K
1 2
3
4 5

Similar funds

WCM
Weber Capital Management San Francisco, California $100M AUM
FCM
Fourier Capital Management Hong Kong $100M AUM
BIA
Baer Investment Advisory Corte Madera, California $100M AUM 23.87% 1-Year Est. Return
AGAM
Audent Global Asset Management West Hollywood, California $100M AUM 22.83% 1-Year Est. Return
E
Entelevest Coral Gables, Florida $100M AUM
HCM
Hicks Capital Management Columbus, Ohio $100M AUM 14.29% 1-Year Est. Return
AC
Arrow Capital Sydney, Australia $100M AUM 68.52% 1-Year Est. Return
OIS
OneAscent Investment Solutions Birmingham, Alabama $100M AUM 15.97% 1-Year Est. Return

AlphaCentric Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, AlphaCentric Advisors held 262 positions worth $136M, down 18% from $166M the previous quarter. Its ten largest holdings account for 25% of the portfolio.

AlphaCentric Advisors withdrew a net $21.6M in Q2 2024, closing 45 positions and reducing 87 holdings. Its most notable exit was UroGen Pharma, an estimated $2.16M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 61% a quarter earlier, followed by Real Estate and Financials.

Against the trend, AlphaCentric Advisors opened a new position in Enovis worth $904K.

  • AlphaCentric Advisors's largest Q2 2024 buy was Enovis: 20,000 shares worth $904K.
  • AlphaCentric Advisors added most to Invesco QQQ Trust in Q2 2024, an estimated $958K increase.
  • AlphaCentric Advisors's biggest Q2 2024 reduction was Inari Medical, Inc. Common Stock, cutting an estimated $2.13M.
  • AlphaCentric Advisors fully exited UroGen Pharma in Q2 2024, selling an estimated $2.16M.
  • AlphaCentric Advisors's ten largest holdings make up 25% of its $136M portfolio in Q2 2024.
  • AlphaCentric Advisors opened 34 new positions and closed 45 in Q2 2024.
  • AlphaCentric Advisors's portfolio value fell 18% quarter-over-quarter to $136M.

Based on AlphaCentric Advisors's 13F filing for Q2 2024, filed 25 Jul 2024.